Linker Information
General Information of This Linker
| Linker ID |
LIN0ROKEJ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
RED-601 linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
|
|
||||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
XB010 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18; ECOG 0-1; adequate organ function; histologically confirmed advanced/metastatic solid tumors (NSCLC, HR+ BC, HNSCC, ESCC, TNBC); protocol compliance capability with signed informed consent.
|
||||
| Administration Dosage |
IV administration of XB010
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06545331 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include MTD/RDE determination (18 months), safety profile (AE/SAE incidence), tolerability (exposure duration/dose intensity), and preliminary antitumor activity (ORR per RECIST 1.1) for XB010 monotherapy and combination therapy.
|
||||
| Other Endpoint |
Secondary endpoints comprise PK parameters (Cmax, Tmax, clearance, AUC, Cmin) and immunogenicity (ADA analysis) for both dose-escalation (18 months) and cohort-expansion stages (24 months), along with continued tolerability assessments.
|
||||